MX340807B - Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. - Google Patents

Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.

Info

Publication number
MX340807B
MX340807B MX2012004548A MX2012004548A MX340807B MX 340807 B MX340807 B MX 340807B MX 2012004548 A MX2012004548 A MX 2012004548A MX 2012004548 A MX2012004548 A MX 2012004548A MX 340807 B MX340807 B MX 340807B
Authority
MX
Mexico
Prior art keywords
preventing
nervous system
central nervous
degenerative disorders
novel compositions
Prior art date
Application number
MX2012004548A
Other languages
English (en)
Other versions
MX2012004548A (es
Inventor
Lee Gary
Boyd Robert
Rybczynski Philip
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2012004548A publication Critical patent/MX2012004548A/es
Publication of MX340807B publication Critical patent/MX340807B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos, así como también composiciones y métodos que los usan para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. En particular, la presente invención proporciona métodos para prevenir y/o tratar la enfermedad de Parkinson.
MX2012004548A 2009-10-19 2010-10-05 Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. MX340807B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25280309P 2009-10-19 2009-10-19
PCT/US2010/051447 WO2011049736A1 (en) 2009-10-19 2010-10-05 Novel compositions for preventing and/or treating degenerative disorders of the central nervous system

Publications (2)

Publication Number Publication Date
MX2012004548A MX2012004548A (es) 2012-07-04
MX340807B true MX340807B (es) 2016-07-27

Family

ID=43879775

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012004548A MX340807B (es) 2009-10-19 2010-10-05 Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
MX2016000153A MX368459B (es) 2009-10-19 2010-10-05 Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016000153A MX368459B (es) 2009-10-19 2010-10-05 Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.

Country Status (27)

Country Link
US (4) US8604206B2 (es)
EP (2) EP3143875B1 (es)
JP (2) JP5805649B2 (es)
KR (3) KR101769396B1 (es)
CN (2) CN105367485B (es)
AR (1) AR078606A1 (es)
AU (3) AU2010308396B2 (es)
BR (1) BR112012009121A2 (es)
CA (1) CA2778348C (es)
CY (1) CY1118966T1 (es)
DK (1) DK2490532T3 (es)
ES (2) ES2814178T3 (es)
HK (1) HK1219724A1 (es)
HR (1) HRP20170236T1 (es)
HU (1) HUE033116T2 (es)
IL (1) IL219160B (es)
LT (1) LT2490532T (es)
MX (2) MX340807B (es)
PL (1) PL2490532T3 (es)
PT (1) PT2490532T (es)
RS (1) RS55679B1 (es)
RU (2) RU2581058C2 (es)
SG (1) SG10201507159XA (es)
SI (1) SI2490532T1 (es)
SM (1) SMT201700105B (es)
TW (1) TWI642434B (es)
WO (1) WO2011049736A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2490532T3 (pl) 2009-10-19 2017-05-31 Amicus Therapeutics, Inc. Nowe kompozycje do zapobiegania i/lub leczenia zaburzeń zwyrodnieniowych ośrodkowego układu nerwowego
ES2716871T3 (es) 2009-10-19 2019-06-17 Amicus Therapeutics Inc Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal
EP2591823A1 (en) * 2011-11-11 2013-05-15 Biologische Heilmittel Heel GmbH Composition for treating or preventing neurodegenerative disorders
CA2868459A1 (en) 2012-03-27 2013-10-03 Amicus Therapeutics, Inc. Polymorphs of (3r,4r,5s)-5-(difluoromethyl)piperidine-3,4-diol fumarate and uses thereof
WO2015095963A1 (en) * 2013-12-23 2015-07-02 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
US10179128B2 (en) 2015-08-31 2019-01-15 Amicus Therapeutics, Inc. Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
US11358926B2 (en) 2017-04-25 2022-06-14 Amicus Therapeutics, Inc. Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders
RU2676956C1 (ru) * 2017-08-25 2019-01-11 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Антитела для связывания имиглюцеразы и их применение в аффинной хроматографии
KR101991276B1 (ko) 2018-01-19 2019-06-21 전남대학교산학협력단 신규 균주 페니실리움 아쿠아티쿰 및 이를 이용한 퇴행성 뇌질환 치료제
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
US20240252418A1 (en) * 2023-01-31 2024-08-01 Bioeutectics Corporation Additives (Adjuvants, Anti Freezing Agents, Antimicrobial and Antioxidants) in Natural Deep Eutectic Solvents and Mixtures

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
AU666118B2 (en) 1991-04-25 1996-02-01 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
DE69332105T2 (de) 1992-09-29 2003-03-06 Inhale Therapeutic Systems, San Carlos Pulmonale abgabe von aktiven fragmenten des parathormons
DE69531098T2 (de) 1994-03-09 2004-04-29 Novo Nordisk A/S Piperidine und pyrrolidine
US5863903A (en) * 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US20040082641A1 (en) * 2002-10-28 2004-04-29 Rytved Klaus Asger Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
AU2003273762A1 (en) * 2002-10-28 2004-05-13 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US7446098B2 (en) 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
JP2007516294A (ja) * 2003-12-23 2007-06-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 炎症性の疾患または症状の予防および治療のための方法および組成物
ES2364586T3 (es) * 2006-05-24 2011-09-07 Amicus Therapeutics, Inc. Sal tartrato de isofagomina y métodos de uso.
US7501439B2 (en) * 2006-05-24 2009-03-10 Amicus Therapeutics, Inc. Tartrate salt of isofagomine and methods of use
BRPI0713442A2 (pt) * 2006-06-23 2012-03-06 Amicus Therapeutics, Inc. Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase
MX2009011473A (es) 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
AU2010233188B2 (en) 2009-04-09 2015-07-16 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders
ES2505243T3 (es) 2009-04-09 2014-10-09 Amicus Therapeutics, Inc. Agentes terapéuticos para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
ES2716871T3 (es) * 2009-10-19 2019-06-17 Amicus Therapeutics Inc Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal
PL2490532T3 (pl) * 2009-10-19 2017-05-31 Amicus Therapeutics, Inc. Nowe kompozycje do zapobiegania i/lub leczenia zaburzeń zwyrodnieniowych ośrodkowego układu nerwowego
ES2646099T3 (es) * 2009-10-19 2017-12-12 Amicus Therapeutics, Inc. Método para el tratamiento de la enfermedad de Alzheimer utilizando chaperonas farmacológicas para aumentar la actividad de gangliosidasas
KR102023720B1 (ko) 2012-09-03 2019-09-20 엘지이노텍 주식회사 보이스 코일 모터

Also Published As

Publication number Publication date
ES2617192T3 (es) 2017-06-15
TW201116279A (en) 2011-05-16
CA2778348A1 (en) 2011-04-28
CN102655747A (zh) 2012-09-05
HRP20170236T1 (hr) 2017-04-07
PT2490532T (pt) 2017-02-23
RS55679B1 (sr) 2017-07-31
KR101880411B1 (ko) 2018-07-19
EP2490532B1 (en) 2016-11-23
HK1219724A1 (zh) 2017-04-13
SG10201507159XA (en) 2015-10-29
CY1118966T1 (el) 2018-01-10
PL2490532T3 (pl) 2017-05-31
MX368459B (es) 2019-10-03
HUE033116T2 (en) 2017-11-28
EP2490532A1 (en) 2012-08-29
EP2490532A4 (en) 2013-06-12
IL219160B (en) 2018-12-31
US20110092541A1 (en) 2011-04-21
EP3143875B1 (en) 2020-05-27
RU2015147509A (ru) 2019-01-14
US8604206B2 (en) 2013-12-10
BR112012009121A2 (pt) 2017-08-29
SMT201700105B (it) 2017-03-08
AU2017272296B2 (en) 2019-07-11
TWI642434B (zh) 2018-12-01
US9409862B2 (en) 2016-08-09
IL219160A0 (en) 2012-06-28
AU2016203817A1 (en) 2016-06-30
KR20120104549A (ko) 2012-09-21
JP5805649B2 (ja) 2015-11-04
ES2814178T3 (es) 2021-03-26
DK2490532T3 (en) 2017-02-27
JP2013508366A (ja) 2013-03-07
AU2017272296A1 (en) 2018-01-25
JP6258245B2 (ja) 2018-01-10
AU2016203817B2 (en) 2017-09-07
KR20170096220A (ko) 2017-08-23
RU2581058C2 (ru) 2016-04-10
KR101813988B1 (ko) 2018-01-02
SI2490532T1 (sl) 2017-03-31
KR20180001588A (ko) 2018-01-04
WO2011049736A1 (en) 2011-04-28
CN105367485B (zh) 2018-04-17
JP2015157822A (ja) 2015-09-03
AR078606A1 (es) 2011-11-23
RU2012120759A (ru) 2013-11-27
AU2010308396A1 (en) 2012-05-03
US20180273474A1 (en) 2018-09-27
AU2010308396B2 (en) 2016-04-28
EP3143875A1 (en) 2017-03-22
MX2012004548A (es) 2012-07-04
US10421724B2 (en) 2019-09-24
CN105367485A (zh) 2016-03-02
US20160326114A1 (en) 2016-11-10
US20140080871A1 (en) 2014-03-20
CA2778348C (en) 2022-08-23
LT2490532T (lt) 2017-03-27
KR101769396B1 (ko) 2017-08-18

Similar Documents

Publication Publication Date Title
MX368459B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
SG179120A1 (en) Novel compounds
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MY161415A (en) A homeopathic formulation
HK1136283A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
MX2010007392A (es) Antagonistas de trpa1.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2010007391A (es) Antagonistas de trpa1.
TW200642690A (en) Composition for treating central nervous system disorders
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
WO2011008675A3 (en) Catecholamine compounds, compositions, and formulations, and methods of using the same
WO2009151618A3 (en) Methods and compositions for treating alzheimer's disease

Legal Events

Date Code Title Description
FG Grant or registration